U.S. Neurodegenerative Disease Market Size, Share & Forecast 2026–2032
Report Highlights
- ✓Country: United States
- ✓Market: Neurodegenerative Disease Market
- ✓Market Size 2024: USD 14.8 billion
- ✓Market Size 2032: USD 27.6 billion
- ✓CAGR: 8.1%
- ✓Base Year: 2025
- ✓Forecast Period: 2026–2032
Analyst Recommendation — Secure Lab Channel Partnerships: Diagnostics vendors and anti-amyloid sponsors should secure multiyear partnerships with Quest Diagnostics or Labcorp before the end of 2026. Blood-based pTau217 testing volume will decide which therapy captures Medicare-covered patients through 2028, so early channel exclusivity locks in share.
Competitive Overview: Neurodegenerative Drugs in the United States
The U.S. neurodegenerative market is concentrated at the top and fragmented beneath it. Eli Lilly, Biogen, Eisai, and Genentech control most branded disease-modifying revenue, while Teva and AbbVie anchor symptomatic and movement-disorder franchises. Device and diagnostics segments remain fragmented, with Medtronic and Abbott competing in deep brain stimulation. Most leaders are American-headquartered, though Eisai and Genentech run U.S. operations through Japanese and Swiss parents, so domestic commercial execution decides share.
Competitive advantage in the United States rests on three factors: Medicare reimbursement strategy, specialist neurology reach, and diagnostic pathway integration. Anti-amyloid therapies require confirmed pathology through PET or plasma biomarkers, plus MRI monitoring for amyloid-related imaging abnormalities. Firms that secure hospital and imaging partnerships therefore outperform rivals with superior trial data alone. Payers now demand real-world outcome evidence before granting coverage, which rewards registry investment.
Demand Drivers Shaping Neurodegenerative Care in America
Population aging is the foundational driver. Roughly one million Americans live with Parkinson's disease, and nearly seven million aged 65 and older live with Alzheimer's dementia. Biogen and Eisai gain most from this volume because Leqembi's infusion-center footprint scales with diagnosed cohorts, while Teva's generic carbidopa-levodopa franchise captures the symptomatic baseline. Diagnosed cohorts are growing fastest among patients aged 75 and older, the group that anchors infusion demand.
Anti-amyloid approvals constitute the second driver. Eli Lilly's Kisunla, approved by the FDA in July 2024, entered a market where Leqembi already held traditional approval, creating two-brand competition in infusion therapy. Lilly benefits from a finite dosing duration that lowers lifetime cost per patient. Huntington's chorea adds a third driver, where Teva's Austedo and Neurocrine's Ingrezza sustain a duopoly in VMAT2 inhibitors.
Competitive Restraints and Market Challenges
Price competition is intensifying as Medicare negotiation under the Inflation Reduction Act extends to high-spend drugs. Biogen withdrew Aduhelm in 2024 after weak uptake, showing that payer scrutiny and CMS coverage-with-evidence-development requirements can erase a launch. Generic carbidopa-levodopa keeps symptomatic pricing deflationary, squeezing mid-tier brands that lack differentiated formulations. Commercial payers increasingly mirror federal prior-authorization rules, adding administrative cost to each infusion.
Talent and infrastructure gaps constrain competitors more than price. Neurologist supply is thin outside metropolitan areas, and many rural counties lack a board-certified neurologist for diagnosis or treatment initiation. Infusion capacity and MRI scanners are concentrated in academic medical centers, which limits how quickly anti-amyloid therapies can scale to community practices and slows return on field-force investment. Staffing shortages also raise infusion nursing costs.
Growth Opportunities for Market Players
Blood-based biomarker testing represents the largest near-term opening. Fujirebio's plasma pTau217 assay, cleared by the FDA in 2025, lets primary care physicians triage patients before referral, and Quest Diagnostics and Labcorp are positioned to scale that volume through existing draw networks. C2N Diagnostics and Quanterix target the same funnel with mass-spectrometry and digital immunoassay platforms, rewarding companies that embed testing into electronic health record workflows.
Neuromodulation and digital monitoring form the second opportunity. Medtronic and Abbott supply deep brain stimulation systems for advanced Parkinson's, and Medtronic's BrainSense adaptive DBS received FDA approval in 2025, rewarding device specialists who secure reimbursement. Biogen's Qalsody, the first tofersen therapy for SOD1-linked ALS approved in 2023, opens a rare-disease niche where orphan pricing and genetic testing partnerships determine patient access.
Market at a Glance
| Metric | Value |
|---|---|
| Market Size 2024 | USD 14.8 billion |
| Market Size 2032 | USD 27.6 billion |
| Growth Rate (CAGR) | 8.1% |
| Most Critical Decision Factor | Payer reimbursement access and diagnostic pathway integration |
| Largest Region | South (largest patient population) |
| Competitive Structure | Oligopolistic in disease-modifying therapies; fragmented in devices and diagnostics |
Leading Market Participants
- Eli Lilly and Company
- Biogen
- Eisai
- Genentech
- AbbVie
- Teva Pharmaceutical Industries
- Neurocrine Biosciences
- Medtronic
- Quest Diagnostics
- Fujirebio
Regulatory and Policy Environment
The FDA's accelerated approval pathway, used for Aduhelm in 2021, now carries higher evidentiary standards following Aduhelm's 2024 withdrawal. Leqembi and Kisunla secured traditional approvals, and the agency's breakthrough and fast-track designations shape which sponsors reach the market first. The FDA cleared Fujirebio's plasma assay in 2025 as an aid for amyloid pathology, creating a regulatory template that diagnostics competitors must now follow.
CMS coverage with evidence development requires anti-amyloid antibody recipients to enroll in a national registry, adding administrative burden that favors large sponsors. The Inflation Reduction Act introduced Medicare price negotiation and capped Part D out-of-pocket spending at $2,000 in 2025, reshaping oral and symptomatic drug economics. The National Alzheimer's Project Act coordinates federal research funding through the NIH, sustaining the pipeline of new entrants.
Competitive Outlook for Neurodegenerative Drugs in America
By 2032, competition will shift from drug efficacy toward diagnostic throughput and payer evidence. Eli Lilly and Eisai will contest the anti-amyloid franchise through subcutaneous maintenance dosing and expanded primary care screening, while Biogen defends its installed base through its ALS and neuroimmunology portfolio. AbbVie's acquisition of Cerevel Therapeutics in 2024 signals that large pharma will buy late-stage neuroscience assets rather than build them.
Symptomatic Parkinson's and Huntington's markets will consolidate around generics and branded VMAT2 and dopamine specialists, compressing margins. Diagnostics leaders with clinician reach, including Quest Diagnostics, Labcorp, and Fujirebio, will capture a growing share of value as testing precedes treatment. Companies without a diagnostic pathway or a Medicare evidence strategy will exit the disease-modifying segment by the end of the forecast period.
Frequently Asked Questions
Market Segmentation
- Alzheimer's Disease
- Parkinson's Disease
- Amyotrophic Lateral Sclerosis
- Huntington's Disease
- Frontotemporal Dementia
- Disease-Modifying Therapies
- Symptomatic Medications
- Neuromodulation Devices
- Diagnostic Assays
- Hospital Pharmacies
- Specialty Pharmacies
- Infusion Centers
- Retail Pharmacies
Table of Contents
Research Framework and Methodological Approach
Information
Procurement
Information
Analysis
Market Formulation
& Validation
Overview of Our Research Process
MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.
1. Data Acquisition Strategy
Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.
- Company annual reports & SEC filings
- Industry association publications
- Technical journals & white papers
- Government databases (World Bank, OECD)
- Paid commercial databases
- KOL Interviews (CEOs, Marketing Heads)
- Surveys with industry participants
- Distributor & supplier discussions
- End-user feedback loops
- Questionnaires for gap analysis
Analytical Modeling and Insight Development
After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.
2. Market Estimation Techniques
MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.
Bottom-up Approach
Aggregating granular demand data from country level to derive global figures.
Top-down Approach
Breaking down the parent industry market to identify the target serviceable market.
Supply Chain Anchored Forecasting
MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.
Supply-Side Evaluation
Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.
3. Market Engineering & Validation
Market engineering involves the triangulation of data from multiple sources to minimize errors.
Extensive gathering of raw data.
Statistical regression & trend analysis.
Cross-verification with experts.
Publication of market study.
Client-Centric Research Delivery
MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.